MIB-1 labeling index as a prognostic indicator for survival in patients with FIGO stage IB squamous cell carcinoma of the cervix

Gynecologic Oncology

Volumn 76, Issue 1, 2000, Pages 97-102

  Ho, Donald Ming Tak ^a,b   Hsu, Chih Yi ^a,b   Chiang, Hung ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

MIB 1; Prognosis; Squamous cell carcinoma; Uterine cervix

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; LABELING INDEX; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; RADICAL HYSTERECTOMY; SQUAMOUS CELL CARCINOMA; TUMOR VOLUME; UTERINE CERVIX CARCINOMA;

EID: 0033963199     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1999.5663     Document Type: Article

References (26)

1. Brown D C, Cole D, Gatter K C, Mason D Y. Carcinoma of the cervix uteri: an assessment of tumour proliferation using the monoclonal antibody Ki67. Br J Cancer. 57:1988;178-181.
2. Boyce J, Fruchter R O, Nicastri A D, Amliavegar P C, Reinis M S, Nelson J H. Prognostic factors in stage I carcinoma of the cervix. Gynecol Oncol. 12:1981;154-165.
3. Burghardt E, Pickel H, Haas J, Lahousen M. Prognostic factors and operative treatment of stage IB to IIB cervical cancer. Am J Obstet Gynecol. 156:1987;988-996.
4. van Bommell P FJ, van Lindert A CM, Kock H CLV, Leers W H, Neijt J P. A review of prognostic factors in early-stage carcinoma of the cervix (FIGO IB and IIA) and implications for treatment strategy. Eur J Obstet Gynecol Reprod Biol. 26:1987;69-84.
5. Hall S M, Monaghan J M. Invasive carcinoma of the cervix in younger women. Lancet. 2:1983;731.
6. Wiernik G. The combination of radiotherapy and surgery in the treatment of carcinoma of the uterine cervix. Br J Radiol. 59:1986;97-105.
7. Gerdes J, Lemke H, Basich H, Wacker H-H, Schwab U, Stein H. Cell cycle analysis of a cell proliferation associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 133:1984;1710-1715.
8. Viberti L, Papotti M, Abbona G C, Celano A, Filosso P L, Bussolati G. Value of Ki-67 immunostaining in preoperative biopsies of carcinomas of the lung. Hum Pathol. 28:1997;189-192.
9. Jansen R L, Hupperets P S, Arends J W, Joosten-Achjanie S R, Volovics A, Schouten H C, Hillen H F. MIB-1 labelling index is an independent prognostic marker in primary breast cancer. Br J Cancer. 78:1998;460-465.
10. Mochen C, Giardini R, Costa A, Silvestrini R. MIB-1 and S-phase cell fraction predict survival in non-Hodgkin's lymphomas. Cell Prolif. 30:1997;37-47.
11. Abramovich C M, Prayson R A. MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: a study of 90 tumors. Hum Pathol. 29:1998;1420-1427.
12. Avall-Lundqvist E H, Silfversward C, Aspenblad U, Nilsson B R, Auer G U. The impact of tumour angiogenesis, p53 overexpression and proliferative activity (MIB-1) on survival in squamous cervical carcinoma. Eur J Cancer. 33:1997;1799-1804.
13. Bar J K, Harlozinska A, Markowska J, Nowak M. Studies on tumor proliferation using monoclonal antibody, Ki 67 and expression of p53 in cancer of the uterine cervix. Eur J Gynaecol Oncol. 17:1996;378-380.
14. Cole D J, Brown D C, Crossley E, Alcock C J, Gatter K C. Carcinoma of the cervix uteri: an assessment of the relationship of tumour proliferation to prognosis. Br J Cancer. 65:1992;783-785.
15. Dellas A, Schultheiss E, Almendral A C, Gudat F, Oberholzer M, Feichter G, Moch H, Torhorst J. Altered expression of mdm-2 and its association with p53 protein status, tumor-cell-proliferation rate and prognosis in cervical neoplasia. Int J Cancer. 74:1997;421-425.
16. Garzetti G G, Ciavattini A, Lucarini G, Goteri G, De Nictolis M, Muzzioli M, Fabris N, Romanini C, Biagini G. MIB 1 immunostaining in stage I squamous cervical carcinoma: relationship with natural killer cell activity. Gynecol Oncol. 58:1995;28-33.
17. Garzetti G G, Ciavattini A, Lucarini G, Goteri G, De Nictolis M, Biagini G. MIB 1 immunostaining in cervical carcinoma of young patients. Gynecol Oncol. 67:1997;184-187.
18. Nakano T, Oka K. Differential value of Ki-67 index and mitotic index of proliferating cell population. An assessment of cell cycle and prognosis in radiation therapy for cervical cancer. Cancer. 72:1993;2401-2408.
19. Oka K, Nakano T, Arai T. Expression of proliferation-associated antigens in cervical carcinoma: correlations among indexes. Pathol Res Pract. 191:1995;997-1003.
20. Wong W S, McGuire L J. Tumor growth fraction in cervical carcinoma. Gynecol Oncol. 40:1991;48-54.
21. Wong F W. Immunohistochemical detection of proliferating tumor cells in cervical cancer using monoclonal antibody Ki-67. Gynecol Obstet Invest. 37:1994;123-126.
22. Wentz W B, Reagan J W. Survival in cervical cancer with respect to cell type. Cancer. 59:1959;384-388.
23. Wright T C, Ferenczy A, Kurman R J. Carcinoma and other tumors of the cervix. Kurman R J. Blaustein's Pathology of the Female Genital Tract. 1994;279-326 Springer-Verlag, New York.
24. Cattoretti G, Becker M G, Key G, Duchrow M, Schluter C, Galle J, Gerdes J. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB1 and MIB3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol. 168:1992;357-363.
25. Goellner J R. Carcinoma of the cervix. Clinicopathologic correlation of 196 cases. Am J Clin Pathol. 66:1976;775-785.
26. Crissman J D, Makuch R, Budhraja M. Histopathologic grading of squamous cell carcinoma of the uterine cervix. An evaluation of 70 stage Ib patients. Cancer. 55:1985;1590-1596.